secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0000950170-23-049683
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma raises $250M in PIPE financing led by Qatar Investment Authority
--------------------------------------------------------------------------------

- Issues 9,167,723 shares at $27.27/share (Sept 22 close); gross proceeds ~$250M.
- Financing led by QIA, with participation from four large US investment management firms.
- Proceeds to fund acoramidis launch, Phase 3 readouts in achondroplasia, LGMD2I, ADH1, and general corporate purposes.
- PIPE expected to close Sept 27, 2023, subject to customary conditions.
- Company also exploring additional less dilutive financing options to optimize cost of capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/0000950170-23-049683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/bbio-20230925.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer